View on Pubmed.gov 18826641 | View on doi.org 10.1186/1743-42...
Molecular and macromolecular alterations of recombinant adenoviral vectors do not resolve changes in hepatic drug metabolism during infection.
- College of Pharmacy, Division of Pharmaceutics, The University of Texas at Austin, Austin, TX, USA. smcallahan@gmail.com
Abstract
In this report we test the hypothesis that long-term virus-induced alterations in CYP occur from changes initiated by the virus that may not be related to the immune response. Enzyme activity, protein expression and mRNA of CYP3A2, a correlate of human CYP3A4, and CYP2C11, responsive to inflammatory mediators, were assessed 0.25, 1, 4, and 14 days after administration of several different recombinant adenoviruses at a dose of 5.7 x 1012 virus particles (vp)/kg to male Sprague Dawley rats. Wild type adenovirus, containing all viral genes, suppressed CYP3A2 and 2C11 activity by 37% and 39%, respectively within six hours. Levels fell to 67% (CYP3A2) and 79% (CYP2C11) of control by 14 days (p <or= 0.01). Helper-dependent adenovirus, with all viral genes removed, suppressed CYP3A2 (43%) and CYP2C11 (55%) within six hours. CYP3A2 remained significantly suppressed (47%, 14 days, p <or= 0.01) while CYP2C11 returned to baseline at this time. CYP3A2 and 2C11 were reduced by 45 and 42% respectively 6 hours after treatment with PEGylated adenovirus, which has a low immunological profile (p <or= 0.05). CYP3A2 remained suppressed (34%, p <or= 0.05) for 14 days while CYP2C11 recovered. Inactivated virus suppressed CYP3A2 activity by 25-50% for 14 days (p <or= 0.05). CYP2C11 was affected similar manner but recovered by day 14. Microarray and in vitro studies suggest that changes in cellular signaling pathways initiated early in virus infection contribute to changes in CYP.
References
Int J Radiat Biol. 2007 Nov-Dec;83(11-12):743-51
Ther Drug Monit. 2007 Dec;29(6):687-710
Chem Res Toxicol. 2008 Jan;21(1):70-83
Drug Metab Dispos. 2008 Feb;36(2):205-16
Cited by 10 citations (total)
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't
Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus.
Electronic publication date May 12, 2011
Piyanuch Wonganan [...] Maria A Croyle et al.
Clinically relevant doses of helper-dependent adenoviruses (HDAds) provoke the host response against capsid proteins in primates and rodents. To determine...
Journal Article Research Support, N.I.H., Extramural
Influence of method of systemic administration of adenovirus on virus-mediated toxicity: focus on mortality, virus distribution, and drug metabolism.
Electronic publication date February 3, 2009
Michael P Boquet [...] Maria A Croyle et al.
INTRODUCTION
Doses of 2 x 10(12) virus particles/kilogram (vp/kg) and higher of recombinant human adenovirus serotype 5 (HAdV-5) given via the...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •
- •
- •